ELI Lilly has withdrawn its soft tissue sarcoma treatment Lartruvo (olaratumab) from the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting set for next month, on news of drug trial failure.
The drug was being promoted to the PBAC for a new Section 100 listing, Authority Required when used in combination with doxorubicin, for the treatment of patients with locally advanced or metastatic soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery.
See the agenda at pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Feb 19
